We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide (NO) elaboration in cultured human endothelial cells and whether this is associated with the activation of oxidant-sensitive signaling mediating endothelial adhesiveness for monocytes. BACKGROUND Endothelial NO elaboration is impaired in hypercholesterolemia and atherosclerosis, which may be due to elevated concentrations of ADMA, an endogenous inhibitor of NO synthase.
Hypercholesterolemia reduces the biological activity of nitric oxide (NO), impairs endothelium-dependent vasodilation (1), increases platelet aggregation (2) and enhances monocyte adhesion (3) . The mechanism by which hypercholesterolemia impairs the L-arginine/NO pathway is probably multifactorial and dependent upon the stage of atherosclerosis (4, 5) . Most studies have reported that the defect is reversed by exogenous L-arginine (6 -9) . Recently, asymmetric dimethylarginine (ADMA) has been characterized to be an endogenous, competitive inhibitor of NO synthase (10) . Asymmetric dimethylarginine has been shown to be synthesized by human endothelial cells (11) . The plasma level of ADMA is elevated, and endothelial NO elaboration is impaired in hypercholesterolemic rabbits as well as in humans with atherosclerosis or with risk factors for atherosclerosis (12) (13) (14) (15) (16) (17) .
Chronic supplementation with the NO precursor L-arginine restores endothelial function and inhibits atherosclerosis (18 -22) and even induces regression (22) . Conversely, chronic inhibition of NO synthase promotes monocyte adhesion and atherogenesis (23) (24) (25) (26) . Therefore, it is possible that elevated ADMA levels in hypercholesterolemic humans may promote atherosclerosis. Indeed, we have recently reported that ADMA is a better predictor of carotid artery intimal-medial thickness (as measured by B-mode ultrasound) than the traditional risk factors (17) .
An important mechanism by which NO may act as an antiatherogenic molecule is by inhibiting endothelial adhesiveness for monocytes (27) . Reduced NO elaboration has been shown to be associated with increased oxidative stress in endothelial cells (28) , which, in turn, activates the oxidant-responsive transcription factor NF-B (29) , leading to enhanced endothelial adhesiveness associated with expression of adhesion molecules like vascular cell adhesion molecule and monocyte chemotactic protein-1 (30 -33) .
In this study we determined that ADMA affects endothelial cell-monocyte interactions in vitro, and we investigated the mechanism leading to this effect.
METHODS
Cell culture. The spontaneously transformed human umbilical vein endothelial cell line ECV 304 (ATCC, Rockville, Maryland [34] ) was cultured in medium M199 (Irvine Scientific) containing 10% fetal calf serum, 100 U/mL penicillin and 100 g/mL streptomycin (Gibco BRL, Grand Island, New York). This cell line retains many of the characteristics of primary endothelial cells including the synthesis of angiotensin-converting enzyme, NO and prostacyclin and the expression of endothelial adhesion molecules including intercellular adhesion molecule-1 and lymphocyte function associated antigen-3. The expression of these adhesion molecules is upregulated by interleukin-1, tumor necrosis factor-␣ and lipopolysaccharide stimulation (35) .
Human monocytoid cells (THP-1) (ATCC) were cultured in RPMI medium 1640 (Irvine Scientific) supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100 g/mL streptomycin. The viability of THP-1 cells was assessed before each experiment using trypan blue exclusion and was always Ͼ95%.
Isolation of low-density lipoproteins (LDL).
Human plasma from two to three donors was obtained from the Stanford blood bank, and butylated hydroxytoluene (BHT) and EDTA were immediately added to the plasma to achieve final concentrations of 20 M and 0.1%, respectively. Plasma was then mixed for 15 min at 4°C before sequential gradient ultracentrifugation (1.019 to 1.063 g/mL adjusted with KBr) as described by Pritchard et al. (36) . The native LDL (nLDL) solution was then dialyzed against 0.9% NaCl containing 20 M BHT and 0.01% EDTA overnight at 4°C. The cholesterol content of the solution was measured by using a cholesterol oxidase colorimetric kit (Sigma). The nLDL solution was stored at 4°C and used for experiments within 2 weeks. For the preparation of oxidized LDL (oxLDL), nLDL solution was dialyzed against 0.9% saline with 0.01% EDTA overnight to eliminate the antioxidant BHT, and oxidation was induced by adding 5 M CuSO 4 for 24 h at 4°C. Oxidation was stopped by adding BHT (20 M) before using the oxLDL for the experiments. Experimental conditions. Transformed human umbilical vein endothelial cells were seeded onto 75 cm 2 culture flasks and maintained in M199 medium as described above. After 24 h the cells were washed twice with PBS, and fresh medium was added. Cells were then maintained in culture for 1, 2, 3, 5 or 7 days in the presence or absence of nLDL (30, 100 and 300 mg/dL) or oxLDL (3 and 10 mg/dL) before the cells and media were harvested for the measurement of ADMA and symmetric dimethylarginine (SDMA) levels. Endothelial integrity during incubation with nLDL and oxLDL was assessed by measuring the activity of lactate dehydrogenase in conditioned media using a commercially available spectrophotometric assay kit (Sigma).
To assess the effects of dimethylarginines and lipoproteins on NO and monocyte chemotactic protein (MCP-1) production and nuclear factor-B activation, endothelial cells were grown to confluence on six-well culture plates. Cells were then washed twice with PBS, and fresh PBS containing 0.7 mmol/L Ca 2ϩ , 1.1 mmol/L Mg 2ϩ , 2.7 mmol/L K ϩ and 6.1 mmol/L glucose was added. The cells were then incubated for 4 h or 24 h in the presence or absence of ADMA, SDMA or L, N-monomethylarginine (L-NMMA) (each 0.1 to 100 mol/L) or with ADMA in the presence of 1mmol/L L-arginine. In other experiments LDL (30, 100 or 300 mg/dL) or oxLDL (1 or 3 mg/dL) or lipoproteins plus 1 mmol/L L-arginine were added to the incubation medium. For the determination of endothelial cell NO formation, the cells were stimulated with calcium ionophore A23187 (1 mol/L). After the end of the incubation time, media were collected, and the cells were gently detached with 5 mmol/L EDTA. Cells were counted in a hemocytometer and subsequently lysed, and incubation media and cell lysates were stored at Ϫ20°C until analysis. em ϭ 450 nm. Samples were eluted from the column with 0.96% citric acid/methanol 70:30, pH 6.8, at a flow rate of 1 mL/min. The variability of the method was below 7%; the detection limit of the assay was 0.15 mol/L. Endothelial cell NO elaboration. The concentration of nitrogen oxides (NO x ) in supernatants from incubation experiments of endothelial cells with dimethylarginines was measured with a commercially available chemiluminescence apparatus (model 2108, Dasibi) after reduction of the samples in boiling acidic vanadium (III) at 98°C as previously described (22, 23) . Boiling acidic vanadium quantitatively reduces NO 2 Ϫ and NO 3 Ϫ to NO, which is quantified by the chemiluminescence detector after reaction with ozone. Signals from the detector were analyzed by a computerized integrator and recorded as areas under the curve. Standard curves for NO x were linear over the range of 50 pmol to 5 nmol/L (R 2 ϭ 0.997). The detection limit of this assay was 65 pmol/L; intra-and interassay variability was Ͻ6%. Superoxide radical release by endothelial cells. For the measurement of endothelial cell superoxide radical release, cells were seeded into 12 mm scintillation counter vials (Packard, Downers Grove, Illinois) and grown to confluence. After 24 h exposure to experimental agents, the cells were washed with fresh PBS and incubated in PBS containing 250 mol/L of lucigenin. Photon emission was recorded in a Packard Tricarb 1,500 liquid scintillation analyzer in the single photon emission mode until equilibration was reached. The cells were then exposed to phorbol-12-myristate-13-acetate (PMA, 2 mol/L dissolved in dimethylsulfoxide), and photon emission was recorded for 15 min. The specific chemiluminescence response was expressed as counts per minute minus the average background activity. After the end of the measurements, the cells were gently detached with 5 mmol/L EDTA, and cell protein was measured (37) 6 ) at a final concentration of 5 g/mL was coated onto 96 well immunoplates overnight. After washing with PBS containing EDTA and Tween 20 (wash buffer), the plates were incubated with blocking buffer (PBS containing 0.2% Triton X-100 and 1% bovine serum albumin, pH 7.2) for 1 h at 37°C. Plates were washed with wash buffer, and 200 L of serially diluted samples or standards was added. After incubation for 2 h with shaking, the wells were rinsed with wash buffer. Monoclonal mouse-antihuman MCP-1 antibody (200 L per well of 5 g/mL) was then added and incubated for 90 min at 37°C. After washing the wells were incubated with alkaline phosphatase-conjugated rabbit-antimouse IgG monoclonal antibody (Sigma) for 90 min at 37°C. Phosphatase substrate (Sigma; 1 mg/mL) was then added. After 30 min of incubation at room temperature, the products were measured at 405 nm by a microplate reader (Biotek). The standard curve for MCP-1 measured by this ELISA was linear from 0.3 to 50 ng/mL; the detection limit was 1 ng/mL. Electrophoretic mobility shift assay. Endothelial cells were harvested, centrifuged to pellet cells and resuspended in ice-cold PBS. Nuclear extracts were prepared according to a modification of the procedure described by Dignam et al. (32) 
oligonucleotide corresponding with the published NF-Bbinding domain. Reactions were performed with 32 Plabeled DNA oligonucleotide in the presence of (in mmol/L) MgCl 2 1, EDTA 0.5, DTT 0.5, NaCl 50, Tris-HCl 10 (pH 7.5) and 0.05 g/mL polydeoxyinosinicdeoxycytidylic acid in 20 vol% glycerol. Samples were separated on a 4% nondenaturating polyacrylamide gel and exposed to x-ray film overnight.
Drugs.
Asymmetric dimethylarginine and symmetric dimethylarginine were purchased from Alexis (San Diego, California). Unless noted, all other drugs were obtained from Sigma (St. Louis, Missouri). Calculations and statistical analysis. All data are given as mean Ϯ SEM. Cell binding data are expressed as the mean relative number of cells bound per high power field (cells/ hpf) from the analysis of 30 fields per culture well. Statistical significance was tested in all experiments using analysis of variance followed by Fisher protected least significant difference test. Statistical significance was assumed for p Ͻ 0.05.
RESULTS
ADMA elaboration by endothelial cells. The concentrations of ADMA and SDMA in ECV 304 human endothelial cell incubation medium were 1.1 Ϯ 0.1 and 0.6 Ϯ 0.2 mol/L, respectively, on day 1. They gradually increased to 3.0 Ϯ 0.5 and 1.9 Ϯ 0.3 mol/L on day 7 (Fig. 1A) . From these data it was calculated that ECV 304 cells released 0.34 Ϯ 0.17 mol ADMA/10 7 cells/24 h and 0.29 Ϯ 0.14 mol SDMA/10 7 cells/24 h into the medium. L-arginine concentrations in the medium were 120 to 160 mol/10 7 cells without significant changes throughout the experimental period. The basal intracellular concentrations of L-arginine, ADMA and SDMA were 426.5 Ϯ 51.5, 3.2 Ϯ 0.6 and 3.9 Ϯ 0.6 mol/g of cell protein, respectively. Given a mean endothelial cell volume of approximately 1.02 pL (34) , the intracellular concentrations of ADMA and SDMA were calculated to be 7.9 Ϯ 1.3 mol/L and 6.2 Ϯ 3.6 mol/L at baseline and increased to 39.4 Ϯ 6.3 and 15.1 Ϯ 6.7 mol/L on day 7. At any time point, the intracellular DMA levels were 8 to 12-fold higher than the concentrations in the conditioned medium.
Incubation with nLDL or oxLDL concentration dependently increased ADMA release by endothelial cells (Fig.  1B) . Transformed ECV 304 human umbilical vein endothelial cells released 0.33 Ϯ 0.12, 0.44 Ϯ 0.06 and 0.52 Ϯ 0.10 m ol ADMA/10 7 cells/24 h into the medium in the presence of nLDL (30, 100 and 300 mg/dL, respectively; p Ͻ 0.05 vs. control for 100 and 300 mg/dL nLDL). In the presence of oxLDL (3 and 10 mg/dL), ADMA release was 0.39 Ϯ 0.27 and 0.68 Ϯ 0.14 mol ADMA/10 7 cells/24 h (p Ͻ 0.05 vs. control for 10 mg/dL oxLDL). Lactate dehydrogenase activity in conditioned media from endothelial cells incubated with nLDL or oxLDL was not significantly higher than from control cells (data not shown).
NO and superoxide elaboration by endothelial cells.
Incubation with ADMA or L-NMMA (0.1 to 100 mol/L) concentration-dependently inhibited NO release by ECV 304 cells (Fig. 2, Table 1 ). Coincubation with 1 mmol/L L-arginine reversed the inhibitory effect of ADMA on NO formation.
Concomitantly with the inhibition of NO synthesis, ADMA and L-NMMA increased endothelial superoxide radical elaboration in a concentration-dependent manner (Fig. 3, Table 1 ). The effect of ADMA on endothelial 
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superoxide release was reversed by 1 mmol/L L-arginine. Native low-density lipoprotein (100 mg/dL) stimulated superoxide radical release by about two to three-fold, and oxLDL (3 mg/dL) stimulated superoxide formation by about 9 to 10-fold. Symmetric dimethylarginine had no significant effect on endothelial NO or superoxide radical release. Monocyte adhesion. Asymmetric dimethylarginine and L-NMMA increased the adhesiveness of ECV 304 human endothelial cells for monocytoid cells in a concentrationdependent manner (Fig. 4 , Table 1 ). Symmetric dimethylarginine had no significant effect on monocyte binding. 
DISCUSSION
The salient findings of our study are that: 1) intracellular ADMA levels are about 10-fold higher than the reported range for plasma values; 2) inhibition of NO production by ADMA increases endothelial superoxide radical elaboration and NF-B activation, resulting in enhanced MCP-1 expression and endothelial adhesiveness for monocytes, and 3) these effects of ADMA are reversed by L-arginine. Vascular NO activity is decreased in hypercholesterolemia and atherosclerosis, leading to impaired endotheliumdependent vasodilation (1), increased platelet aggregability (38, 39) and monocyte adhesiveness for the endothelium (3, 40) . This impaired NO activity may contribute to the development and progression of atherosclerosis. Indeed, in animal models of hypercholesterolemia, pharmacological inhibition of NO synthase promotes atherosclerosis (23) (24) (25) (26) . On the other hand, enhancement of endogenous NO formation with L-arginine supplementation improves endothelial function (6 -9,15), inhibits platelet activation and monocyte adhesiveness for the endothelium (2,3,38 -40) and slows progression of lesions or even induces regression (18 -22,26) . The benefit of L-arginine cannot be attributed to reduced plasma levels of L-arginine in hypercholesterolemia (41, 42) but are more likely due to its reversal of the effects of ADMA, an inhibitor of the NOS pathway (43, 44) . ADMA metabolism. The pathways by which ADMA is synthesized and degraded and the effect of hypercholesterolemia on these pathways are under investigation. The specific enzyme S-adenosylmethionine: protein arginine N-methyltransferase (protein methylase I) has been shown to methylate internal arginine residues in a variety of polypepetides. Catabolism of these polypeptides generates [45] [46] [47] . The metabolism of ADMA, but not SDMA, occurs via hydrolytic degradation to citrulline by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) (48) . Inhibition of DDAH causes a gradual vasoconstriction of vascular segments, which is reversed by L-arginine (46) . This latter finding suggests that inhibition of DDAH regulation could reduce NO synthase activity. We have recently found that exposure of vascular cells to oxidized lipoproteins in vitro increases elaboration of ADMA into the conditioned medium, which is temporally related to a decline in DDAH activity (49) . Moreover, in the hypercholesterolemic rabbit (where plasma ADMA levels are elevated) DDAH activity is reduced in the aorta, liver and kidney (49) . Together, these data and the current investigation suggest that elevated ADMA levels may mediate some of the biological effects of LDL on the endothelium in an autocrine or paracrine manner.
Most importantly, within the concentration range we found in cultured endothelial cells (5 to 40 M), ADMA induced pathophysiological changes of endothelial biology that also occur in hypercholesterolemia. Inhibition of endothelial NO synthase activity is associated with a concentration-dependent increase of endothelial adhesiveness for human THP-1 monocytoid cells. This effect of ADMA and L-NMMA mimics the increase in adhesiveness observed when endothelial cells are preincubated with nLDL; in both cases, adhesion is diminished by coincubating endothelial cells with L-arginine. Supplementation of cholesterol-fed rabbits with L-arginine has previously been shown to reduce aortic endothelial adhesiveness for monocytes (23) . NO and endothelial adhesiveness. Monocyte adhesion to the endothelium is regulated via a variety of different cell surface receptors on monocytes and endothelial cells (50) . In hypercholesterolemia and atherosclerosis, increased expression of vascular adhesion molecule-1 (51) and MCP-1 (52) has been demonstrated. Upregulation of these proteins is induced via increased intracellular oxidative stress, which involves the induction of NF-B-regulated transcriptional pathways (30) . The effects of oxidative stress on NF-B activation are counteracted by NO, resulting in downregulation of the expression of vascular adhesion molecule-1(32) and MCP-1 (53) . Nitric oxide also stabilizes the inhibitory subunit I-B, thereby blocking the activation of NF-B and its binding to specific domains on the DNA (54). Therefore, one can assume that NO activity may regulate mononuclear cell adhesiveness by affecting endothelial cell oxidative stress. Indeed, we found that reduced endothelial NO elaboration by ADMA or L-NMMA was associated with increased superoxide radical-induced oxidative stress, as measured by lucigenin chemiluminescence. L-arginine diminished superoxide anion release. Besides impaired endothelium-dependent vasodilation and increased platelet adhesion and aggregation, this autocrine antioxidant role of NO may play a very important role in its antiatherogenic effects. Limitations and clinical implications. The current study confirms previous observations of our group and others that oxidized lipoprotein increases the endothelial release of ADMA and that ADMA reduces the synthesis of NO while increasing the generation of superoxide anion. However, in this study it took rather high concentrations (10 m) of exogenous ADMA to have a measurable effect upon NO synthesis, superoxide anion generation and endothelial adhesiveness. This concentration of ADMA is at the upper range of plasma ADMA levels observed in disease (2 to 10 m).
However, chronic exposure to the lower levels of ADMA observed in disease states appears to have similar effects on endothelial biology as does short-term exposure to the higher dose used in this study. Specifically, we and others have demonstrated that the two to three-fold increase in plasma ADMA observed in hypercholesterolemic individuals is associated with reductions in endothelium dependent vasodilation and urinary nitrate excretion-effects that are reversed by administration of L-arginine (14, 15) . Moreover, plasma ADMA levels in the subjects correlate better with endothelial vasodilator function than does LDL cholesterol (15) .
The mechanism by which L-arginine exerts its beneficial effects appears to be through enhanced production of endothelium-derived NO (14, 23) . Originally, this was termed the "arginine paradox," because the effect of L-arginine was surprising, given the low K m of the purified endothelial NO synthase (2.9 M) (41) and the relatively high physiological plasma concentrations of L-arginine (60 to 100 mol/L), which are unchanged in hypercholesterolemia (42) .
The "L-arginine paradox" may be explained by the presence of endogenous competitive NO inhibitors such as ADMA (10) . The ADMA plasma levels are approximately 1 mol/L in healthy humans and are elevated two-fold in hypercholesterolemic individuals ( 15) . In elderly patients with peripheral arterial disease and generalized atherosclerosis, plasma ADMA levels range from 2.5 to 3.5 mol/L, corresponding to the severity of the vascular disease (14) . For patients with renal failure, plasma ADMA levels may be elevated nine-fold (10) .
Of note, we find that the intracellular ADMA level within endothelial cells is considerably higher than those in the conditioned media. The same may be true for ADMA levels in endothelial cells in vivo with respect to human Nuclear extracts were isolated from ECV 304 human endothelial cells after incubation with the various substances for 24 h. Binding reactions were carried out by mixing nuclear proteins with a 32 P-labeled double-stranded DNA oligonucleotide corresponding to the published NF-B-binding domain. In some experiments, unlabeled oligonucleotide corresponding to the same NF-B-binding domain ("competitor") or to the SP-1 binding domain ("noncomp") was utilized. This experiment was replicated 3 times. ADMA ϭ asymmetric dimethylarginine; LDL ϭ low-density lipoprotein; MCP-1 ϭ monocyte chemotactic protein; nLDL ϭ native low-density lipoprotein; oxLDL ϭ oxidized low-density lipoprotein; SDMA ϭ symmetric dimethylarginine. (44) , and Fickling et al. (11) reported that 2 and 10 M ADMA inhibited nitrite production in activated macrophages by 17 and 33%, respectively. These data, taken together with the results of this study, suggest that ADMA may be a potential autocrine regulator of endothelial NO synthase.
In conclusion, our study shows that ADMA, an endogenous competitive inhibitor of NO synthesis, increases endothelial superoxide radical formation, increases MCP-1 secretion and enhances adhesiveness of the endothelium for monocytes. Asymmetric dimethylarginine elaboration in endothelial cells is enhanced by LDL. Asymmetric dimethylarginine may act as an autocrine proatherogenic molecule in endothelial cells. Because ADMA is elevated in many disorders associated with atherosclerosis (that is, hypercholesterolemia, hypertension, diabetes mellitus, tobacco use, aging and hyperhomocysteinemia), it may represent one common pathway by which these risk factors induce endothelial dysfunction and atherogenesis.
